Division of Hematology Oncology, Department of Medicine
Cancer Biology | Cell Biology | Cells | Hemic and Immune Systems | Hemic and Lymphatic Diseases | Neoplasms | Therapeutics | Translational Medical Research
Cancer stem cells play a critical role in disease initiation and insensitivity to chemotherapy in numerous hematologic malignancies and some solid tumors, and these stem cells need to be eradicated to achieve a cure. Key to successful targeting of cancer stem cells is to identify and functionally test critical target genes and to fully understand their associated molecular network in these stem cells. Human chronic myeloid leukemia (CML) is well accepted as one of the typical types of hematopoietic malignancies that are derived from leukemia stem cells (LSCs), serving as an excellent model disease for understanding the biology of LSCs and developing effective, selective, and curative strategies through targeting LSCs. Here, we discuss LSCs in CML with a focus on identification of unique biological features of these stem cells to emphasize the feasibility and significance of specific targeting of LSCs while sparing normal stem cell counterparts in leukemia therapy.
BCR-ABL, Bone marrow, Cancer stem cells, Chronic myeloid leukemia, Leukemia
Rights and Permissions
© 2019 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is noncommercial and no modifications or adaptations are made.
DOI of Published Version
Stem Cells Transl Med. 2019 Apr 23. doi: 10.1002/sctm.18-0247. [Epub ahead of print] Link to article on publisher's site
Stem cells translational medicine
Zhang H, Li S. (2019). Exploiting Unique Biological Features of Leukemia Stem Cells for Therapeutic Benefit. Open Access Articles. https://doi.org/10.1002/sctm.18-0247. Retrieved from https://escholarship.umassmed.edu/oapubs/3839
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Cancer Biology Commons, Cell Biology Commons, Cells Commons, Hemic and Immune Systems Commons, Hemic and Lymphatic Diseases Commons, Neoplasms Commons, Therapeutics Commons, Translational Medical Research Commons